Key facts
- It has raised $100K; the latest was Accelerator/Incubator in Jan 2026.
- Notable investors include Incubateur HEC Paris, 21st by CentraleSupélec.
- PatLynk has filed 1 Form D with the SEC, most recently Feb 2025 ($100K sold to 1 investors).
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for PatLynk
- ·The full record, as it builds
Funding rounds
No funding rounds for PatLynk are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About PatLynk
Developer of a personalized matching tool designed to connect patients with suitable clinical trials efficiently. The company's tool uses artificial intelligence to match with suitable clinical trials tailored to health needs and preferences, providing access to a comprehensive and up-to-date database of trials, enabling users to make informed decisions confidently and explore their treatment options easily.
- Sector
- Consumer Products and Services (B2C)
- HQ
- Neuilly-sur-Seine, France
- Founded
- 2024
- Employees
- 7
- Website
- patlynk.com/
- Ownership
- Privately Held (backing)
PatLynk doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in PatLynk shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on PatLynk in its N-PORT filings yet. We sweep new filings monthly.